Medistim Valuation Multiples

Discover revenue and EBITDA valuation multiples for Medistim and similar public comparables like Medmix, Revenio Group, Anbio Biotechnology, Delcath Systems and more.

Medistim Overview

About Medistim

Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.


Founded

1984

HQ

Norway

Employees

154

Financials (LTM)

Revenue: $77M
EBITDA: $24M

EV

$411M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Medistim Financials

Medistim reported last 12-month revenue of $77M and EBITDA of $24M.

In the same LTM period, Medistim generated $62M in gross profit, $24M in EBITDA, and $17M in net income.

Revenue (LTM)


Medistim P&L

In the most recent fiscal year, Medistim reported revenue of $74M and EBITDA of $25M.

Medistim is profitable as of last fiscal year, with gross margin of 81%, EBITDA margin of 34%, and net margin of 23%.

See analyst estimates for Medistim
LTMLast FY202320242025202620272028
Revenue$77M$74M$54M$58M$73M
Gross Profit$62M$59M$42M$46M$59M
Gross Margin81%81%78%80%82%
EBITDA$24M$25M$17M$16M$25M
EBITDA Margin31%34%31%29%34%
EBIT Margin27%28%25%24%28%
Net Profit$17M$17M$11M$11M$16M
Net Margin22%23%20%19%23%

Financial data powered by Morningstar, Inc.

Medistim Stock Performance

Medistim has current market cap of $429M, and enterprise value of $411M.

Market Cap Evolution


Medistim's stock price is $23.49.

Medistim share price increased by 1.8% in the last 30 days, and by 3.2% in the last year.

Medistim has an EPS (earnings per share) of $0.91.

See more trading valuation data for Medistim
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$411M$429M-1.5%1.8%-2.7%3.2%$0.91

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Medistim Valuation Multiples

Medistim trades at 5.3x EV/Revenue multiple, and 17.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Medistim

EV / Revenue (LTM)


Medistim Financial Valuation Multiples

As of July 18, 2026, Medistim has market cap of $429M and EV of $411M.

Medistim has a P/E ratio of 25.6x.

LTMLast FY202320242025202620272028
EV/Revenue5.3x5.6x7.6x7.1x5.7x
EV/EBITDA17.4x16.7x24.9x24.9x16.7x
EV/EBIT19.7x20.2x30.2x30.3x20.2x
EV/Gross Profit6.6x6.9x9.7x9.0x6.9x
P/E25.6x25.7x39.9x39.9x26.0x
EV/FCF24.8x23.6x47.6x33.5x25.8x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Medistim Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Medistim Margins & Growth Rates

Medistim grew revenue by 10% but EBITDA decreased by 0% in the last fiscal year.

In the most recent fiscal year, Medistim reported gross margin of 81%, EBITDA margin of 34%, and net margin of 23%.

See estimated margins and future growth rates for Medistim

Medistim Margins

Last FY202420252026202720282029
Gross Margin81%80%82%80%
EBITDA Margin34%29%34%30%
EBIT Margin28%24%28%27%
Net Margin23%19%23%21%
FCF Margin24%21%22%20%

Medistim Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth10%7%26%11%
Gross Profit Growth9%8%29%9%
EBITDA Growth(0%)(0%)49%(0%)
EBIT Growth8%(0%)50%8%
Net Profit Growth1%0%53%2%
FCF Growth(9%)42%30%(0%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Medistim Operational KPIs

Medistim's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

Medistim's Rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medistim's Rule of X is 59% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Medistim
LTMLast FY202320242025202620272028
Rule of 4040%42%---
Bessemer Rule of X53%59%---
Revenue per Employee-$0.5M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue-2%2%3%2%
G&A Expenses to Revenue-7%8%8%7%
Opex to Revenue-53%53%56%54%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Medistim Competitors

Medistim competitors include Medmix, Revenio Group, Anbio Biotechnology, Delcath Systems, Shoulder Innovations, Imricor Medical Systems, Kamada, ClearPoint Neuro, Carvolix and VieMed.

Most Medistim public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Medmix1.2x1.3x6.4x6.3x
Revenio Group3.1x2.6x10.9x10.6x
Anbio Biotechnology46.8x-70.2x-
Delcath Systems4.2x3.7x14.1x26.6x
Shoulder Innovations7.5x6.1x(9.8x)(10.7x)
Imricor Medical Systems1352.2x198.1x(18.3x)(17.2x)
Kamada1.9x1.8x8.2x7.3x
ClearPoint Neuro13.0x10.5x(31.7x)(26.9x)

This data is available for Pro users. Sign up to see all Medistim competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Medistim

When was Medistim founded?Medistim was founded in 1984.
Where is Medistim headquartered?Medistim is headquartered in Norway.
How many employees does Medistim have?As of today, Medistim has over 154 employees.
Who is the CEO of Medistim?Medistim's CEO is Kari Eian Krogstad.
Is Medistim publicly listed?Yes, Medistim is a public company listed on Oslo Børs.
What is the stock symbol of Medistim?Medistim trades under MEDI ticker.
When did Medistim go public?Medistim went public in 2004.
Who are competitors of Medistim?Medistim main competitors include Medmix, Revenio Group, Anbio Biotechnology, Delcath Systems, Shoulder Innovations, Imricor Medical Systems, Kamada, ClearPoint Neuro, Carvolix, VieMed.
What is the current market cap of Medistim?Medistim's current market cap is $429M.
What is the current revenue of Medistim?Medistim's last 12 months revenue is $77M.
What is the current revenue growth of Medistim?Medistim revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of Medistim?Current revenue multiple of Medistim is 5.3x.
What is the current EBITDA of Medistim?Medistim's last 12 months EBITDA is $24M.
What is Medistim's EBITDA margin?Medistim's last 12 months EBITDA margin is 31%.
What is the current EV/EBITDA multiple of Medistim?Current EBITDA multiple of Medistim is 17.4x.
What is the current FCF of Medistim?Medistim's last 12 months FCF is $17M.
What is Medistim's FCF margin?Medistim's last 12 months FCF margin is 21%.
What is the current EV/FCF multiple of Medistim?Current FCF multiple of Medistim is 24.8x.
How many companies Medistim has acquired to date?Medistim hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Medistim has invested to date?Medistim hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Medistim

Lists including Medistim

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial